Home Authors Posts by Caroline Chen

Caroline Chen

Avatar
14 POSTS 0 COMMENTS

Gilead executive says pharmacy benefit managers keep prices high

NEW YORK - Gilead Sciences Inc.’s hepatitis C cure set off a firestorm of criticism over high drug prices in 2014 that hasn’t let...

Drug industry group starts ad campaign to push back on pricing

SAN FRANCISCO - A top pharmaceutical lobbying group is launching an ad campaign to defend drugmakers that have been under fire for their pricing...

Pfizer beats Sanofi with Medivation deal for $14B

NEW YORK - Pfizer Inc. agreed to buy Medivation Inc. for about $14 billion, gaining a blockbuster prostate-cancer treatment and leaving French drugmaker Sanofi...

Amgen is open to bigger deals while staying disciplined

SAN FRANCISCO - After sitting out for most of the biotech acquisition frenzy of 2015, Amgen Inc. is ready to do a deal.In the...

UnitedHealth unit favors Sanofi, Regeneron cholesterol drug

SAN FRANCISCO - UnitedHealth Group Inc.’s Oxford unit, which runs health plans in the northeastern U.S., will favor Sanofi and Regeneron Pharmaceuticals Inc.’s new...

Amgen posts profit that tops estimates, raises guidance

SAN FRANCISCO - Biotechnology giant Amgen Inc. posted third- quarter earnings that topped analysts’ estimates, driven by higher drug sales, and raised its forecast...

Amgen’s first-of-its-kind skin cancer drug wins U.S. approval

SAN FRANCISCO - Amgen Inc.’s therapy for a deadly form of skin cancer was approved by U.S. regulators, letting the drugmaker move forward even...

Gilead’s gaffe leads drugmakers to pledge more openness on price

SAN FRANCISCO - Drugmakers worried about a backlash over soaring drug prices are increasingly talking with insurers ahead of time about paying for new...

Bracing for biotech copycats, Amgen plans its own imitations

WASHINGTON - At a state-of-the-art facility in Thousand Oaks, Calif., drugmaker Amgen Inc. is perfecting the art of copying others.The 25,000-square-foot (2,300-square-meter) plant is...

Gilead makes exclusive deal with CVS for Hepatitis C drugs

NEW YORK - Gilead Sciences Inc. agreed to make its hepatitis C medicines the exclusive treatments for CVS Health Corp. customers, intensifying a drug-industry...
- Featured Event -

Latest News